Brookstone Capital Management Has $3.67 Million Stake in Pfizer Inc. (NYSE:PFE)

Brookstone Capital Management boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 37.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 122,054 shares of the biopharmaceutical company’s stock after acquiring an additional 33,024 shares during the period. Brookstone Capital Management’s holdings in Pfizer were worth $3,665,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Olistico Wealth LLC acquired a new position in shares of Pfizer during the second quarter valued at about $25,000. Creekmur Asset Management LLC acquired a new position in shares of Pfizer during the fourth quarter valued at about $32,000. Trivant Custom Portfolio Group LLC raised its position in shares of Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 600 shares during the last quarter. Tennessee Valley Asset Management Partners acquired a new position in shares of Pfizer during the fourth quarter valued at about $36,000. Finally, DiNuzzo Private Wealth Inc. acquired a new position in Pfizer in the fourth quarter worth about $37,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

Pfizer stock traded down $0.41 during trading hours on Friday, hitting $28.30. 50,332,917 shares of the stock were exchanged, compared to its average volume of 39,558,848. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $37.19. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. The business’s 50-day moving average is $28.75 and its two-hundred day moving average is $27.89. The stock has a market capitalization of $160.36 billion, a P/E ratio of -471.59, a P/E/G ratio of 0.99 and a beta of 0.69.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. During the same period in the prior year, the firm earned $0.67 earnings per share. Pfizer’s revenue was up 2.1% compared to the same quarter last year. Equities research analysts expect that Pfizer Inc. will post 2.68 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be paid a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, July 26th. This represents a $1.68 annualized dividend and a dividend yield of 5.94%. Pfizer’s dividend payout ratio (DPR) is currently -2,799.53%.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on PFE shares. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. BMO Capital Markets reissued an “outperform” rating and issued a $36.00 price target (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Barclays increased their price target on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Wells Fargo & Company increased their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Finally, UBS Group increased their price target on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Eight analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $34.54.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.